HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
copovithane
structure given in first source
Also Known As:
2-methylene-1,3-propanediyl-bis(methylcarbamate)-N-vinylpyrrolidone copolymer; Bay i 7433; Bay i-7433
Networked:
5
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Acyclic Hydrocarbons
Alkenes: 265
Vinyl Compounds: 2
Polyvinyls: 183
Povidone: 536
copovithane: 5
Carboxylic Acids: 973
Acyclic Acids
Carbamates: 945
copovithane: 5
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrrolidines: 115
Pyrrolidinones: 162
Povidone: 536
copovithane: 5
Macromolecular Substances: 97
Polymers: 13051
Plastics: 13104
Polyvinyls: 183
Povidone: 536
copovithane: 5
Biomedical and Dental Materials
Polymers: 13051
Plastics: 13104
Polyvinyls: 183
Povidone: 536
copovithane: 5
Technology, Industry, and Agriculture
Manufactured Materials
Biomedical and Dental Materials
Polymers: 13051
Plastics: 13104
Polyvinyls: 183
Povidone: 536
copovithane: 5
Related Diseases
1.
Neoplasms (Cancer)
01/01/1986 - "
However, copovithane does penetrate well to tumor tissues, achieving high tumor/plasma ratios.
"
01/01/1986 - "
In concert with its phase I clinical trial, copovithane concentrations were analyzed by HPLC in plasma, urine, and autopsy and in tumor biopsy specimens obtained from patients.
"
08/01/1986 - "
Ninety-one patients with various metastatic neoplasms beyond the curable stage were treated with copovithane by weekly intravenous administration.
"
04/01/1987 - "
Thirty patients with advanced colorectal carcinoma with measurable tumors were treated in an open randomized study with two schedules of copovithane (schedule A: 6 g/m2 i.v. over 30 min daily for 5 consecutive days and repeated every 3 weeks; schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months).
"
01/01/1986 - "
Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer.
"
2.
Peritonitis
01/01/1989 - "
Copovithane (CPV), a synthetic polymer, has been shown to have antitumor activity and also to reduce mortality in experimental murine peritonitis.
"
05/01/1985 - "
Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immunostimulative polymer.
"
05/01/1985 - "
The purpose of this study was to determine the effect of an immunostimulative polymer, Copovithane (Cpv), plus antibiotics (netilmicin and clindamycin) in a murine model of fecal peritonitis.
"
3.
Colorectal Neoplasms (Colorectal Cancer)
04/01/1987 - "
Copovithane was ineffective against colorectal carcinoma by both schedules selected in this study.
"
04/01/1987 - "
A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma.
"
04/01/1987 - "
Thirty patients with advanced colorectal carcinoma with measurable tumors were treated in an open randomized study with two schedules of copovithane (schedule A: 6 g/m2 i.v. over 30 min daily for 5 consecutive days and repeated every 3 weeks; schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months).
"
4.
Sepsis (Septicemia)
01/01/1989 - "
Evaluation of copovithane as a nonspecific immunomodulator in surgically simulated sepsis.
"
Related Drugs and Biologics
1.
Polymers
2.
Netilmicin (Netromycin)
3.
Clindamycin (Cleocin)
4.
Anti-Bacterial Agents (Antibiotics)
5.
Immunologic Factors (Immunomodulators)
6.
copovithane
Related Therapies and Procedures
1.
Intravenous Administration